CELSA, Ciro
 Distribuzione geografica
Continente #
NA - Nord America 1.796
EU - Europa 647
AS - Asia 420
AF - Africa 9
SA - Sud America 2
OC - Oceania 1
Totale 2.875
Nazione #
US - Stati Uniti d'America 1.792
IT - Italia 362
SG - Singapore 257
DE - Germania 120
CN - Cina 119
GB - Regno Unito 38
FI - Finlandia 27
IE - Irlanda 25
SE - Svezia 18
IN - India 12
HK - Hong Kong 11
RO - Romania 11
RU - Federazione Russa 10
BE - Belgio 8
CI - Costa d'Avorio 7
FR - Francia 5
JP - Giappone 5
KR - Corea 5
NL - Olanda 5
CA - Canada 4
CH - Svizzera 4
AT - Austria 3
ES - Italia 3
PT - Portogallo 3
TW - Taiwan 3
UA - Ucraina 2
VN - Vietnam 2
AF - Afghanistan, Repubblica islamica di 1
AU - Australia 1
BD - Bangladesh 1
BR - Brasile 1
CL - Cile 1
CZ - Repubblica Ceca 1
EG - Egitto 1
GE - Georgia 1
GR - Grecia 1
IL - Israele 1
LB - Libano 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
Totale 2.875
Città #
Chandler 277
Singapore 230
Fairfield 211
Ashburn 155
Woodbridge 83
Palermo 77
Ann Arbor 68
Houston 68
Wilmington 65
Seattle 64
Altamura 63
New York 61
Medford 58
Santa Clara 52
Cambridge 45
Lawrence 36
Princeton 36
Ludwigshafen am Rhein 28
Bremen 27
Dublin 25
Des Moines 24
Rome 22
Helsinki 21
San Diego 21
Beijing 15
London 15
West Jordan 12
Milan 11
Central 9
Columbus 9
Brussels 8
Krefeld 8
Venice 8
Abidjan 7
Boardman 7
Guangzhou 7
Pune 7
Florence 6
Nanjing 6
Bologna 5
Changsha 5
Dallas 5
Dearborn 5
Gallarate 5
Hanover 5
Kilburn 5
Lappeenranta 5
Shenyang 5
Vicopisano 5
Cagliari 4
Jinan 4
Kumar 4
Los Angeles 4
Messina 4
Washington 4
Zhengzhou 4
Aragona 3
Biancavilla 3
Catania 3
Fasano 3
Forest City 3
Jiaxing 3
Nanchang 3
Naples 3
Saint Petersburg 3
Shanghai 3
Suwon 3
Tokyo 3
Aachen 2
Afragola 2
Barcellona Pozzo di Gotto 2
Basel 2
Clifton 2
Cologne 2
Erice 2
Falkenstein 2
Gorgonzola 2
Ho Chi Minh City 2
Hong Kong 2
Las Palmas de Gran Canaria 2
Leawood 2
Mehlingen 2
Misterbianco 2
Mistretta 2
Munich 2
Napoli 2
Ningbo 2
Novellara 2
Oakland 2
Ottawa 2
Paceco 2
Pavia 2
Perugia 2
Pisa 2
Porto 2
Qingdao 2
Rieti 2
Rimini 2
San Francisco 2
Seongnam 2
Totale 2.130
Nome #
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 170
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 139
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 131
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 118
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis 116
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives 114
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 114
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 114
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis 100
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 88
Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE) 69
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? 68
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? 65
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 65
Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis 64
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 62
Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study 57
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals 55
Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials 54
Systemic therapies for hepatocellular carcinoma: The present and the future 54
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison 53
Biochemical biomarkers of NAFLD/NASH 52
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 49
Reply 48
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials 48
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 46
Consequences of Extended Spectrum Beta-Lactamase–Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients 46
Biliary complications after liver transplantation: current perspectives and future strategies 45
Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: A systematic review and meta-analysis 45
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence 43
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 42
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 42
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 42
Identification of clinical phenotypes and related survival in patients with large hccs 42
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 40
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 39
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 38
Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors 37
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD 36
Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients 35
Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC 34
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study 34
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis 34
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology 33
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 32
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma 30
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 30
Reply 25
Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data 24
The price and value of therapeutic synergy in liver cancer 24
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease 23
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals 21
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis 21
Risk profiling of hepatocellular carcinoma occurrence after eradication of hepatitis C virus with direct-acting antiviral agents 20
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 20
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis 18
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 18
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation 17
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies 16
Expert opinion vs. meta-analysis: To be or not to be? 16
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 15
Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma 14
Reply to: “irLI or not irLI: That is the question” 14
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 13
Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data 13
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon 12
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 11
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 11
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice 11
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 11
Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study 11
Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review 8
The Application of Large Language Models in Gastroenterology: A Review of the Literature 6
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 6
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 6
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 6
Evaluating the predictive performance of the elderly patient calculator TIPS score in a North American cohort 5
null 3
null 3
Totale 3.354
Categoria #
all - tutte 22.154
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.154


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020224 0 0 0 0 0 45 24 19 52 34 40 10
2020/2021354 15 18 30 14 34 16 50 29 51 23 39 35
2021/2022534 50 36 16 17 5 14 10 158 70 32 32 94
2022/2023923 60 165 8 112 82 103 89 73 159 10 35 27
2023/2024550 24 54 36 43 19 153 59 17 17 29 32 67
2024/2025667 35 125 217 131 31 128 0 0 0 0 0 0
Totale 3.354